Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group
doi: https://doi.org/10.1101/2022.10.17.22281178
Back to top
Posted October 18, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group
medRxiv 2022.10.17.22281178; doi: https://doi.org/10.1101/2022.10.17.22281178
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area